Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2008 1
2012 2
2017 2
2018 1
2019 2
2020 7
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M. Caputo R, et al. Among authors: di lauro v. Future Oncol. 2023 Aug;19(24):1695-1708. doi: 10.2217/fon-2023-0361. Epub 2023 Aug 22. Future Oncol. 2023. PMID: 37605877 Review.
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice.
Buono G, Arpino G, Del Mastro L, Fabi A, Generali D, Puglisi F, Zambelli A, Cinieri S, Nuzzo F, Di Lauro V, Vigneri P, Bianchini G, Montemurro F, Gennari A, De Laurentiis M. Buono G, et al. Among authors: di lauro v. Front Oncol. 2022 Oct 26;12:1032166. doi: 10.3389/fonc.2022.1032166. eCollection 2022. Front Oncol. 2022. PMID: 36387212 Free PMC article.
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center.
Piezzo M, D'Aniello R, Avallone I, Barba B, Cianniello D, Cocco S, D'Avino A, Di Gioia G, Di Lauro V, Fusco G, Piscitelli R, von Arx C, De Laurentiis M, Maiolino P. Piezzo M, et al. Among authors: di lauro v. Pharmaceutics. 2021 May 10;13(5):684. doi: 10.3390/pharmaceutics13050684. Pharmaceutics. 2021. PMID: 34068626 Free PMC article.
Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study.
Romano FJ, Barbato C, Biglietto M, Di Lauro V, Arundine D, Fiorentino R, Ambrosio F, Cammarota M, Chiurazzi B, Puglia L, Scagliarini S, Ruocco R, Mocerino C, Cerillo I, Brangi MF, Riccardi F. Romano FJ, et al. Among authors: di lauro v. Oncotarget. 2021 Feb 2;12(3):221-229. doi: 10.18632/oncotarget.27872. eCollection 2021 Feb 2. Oncotarget. 2021. PMID: 33613849 Free PMC article.
Targeting Autophagy in Breast Cancer.
Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, Fusco G, Capozzi M, Gioia GD, Budillon A, De Laurentiis M. Cocco S, et al. Among authors: di lauro v. Int J Mol Sci. 2020 Oct 22;21(21):7836. doi: 10.3390/ijms21217836. Int J Mol Sci. 2020. PMID: 33105796 Free PMC article. Review.
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, Munzone E, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini E, Gombos A, Deleu I, Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson A, Graas MP, Barber M, Fontaine C, Loibl S, Gavilá J, Kuroi K, Müller B, O'Reilly S, Di Leo A, Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M. Guerini-Rocco E, et al. Among authors: di lauro v. Clin Cancer Res. 2021 Jan 15;27(2):504-512. doi: 10.1158/1078-0432.CCR-20-0126. Epub 2020 Oct 20. Clin Cancer Res. 2021. PMID: 33082214 Clinical Trial.
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Ottaviano M, et al. Among authors: di lauro v. J Immunother Cancer. 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. J Immunother Cancer. 2020. PMID: 33060148 Free PMC article.
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M, De Laurentiis M. Piezzo M, et al. Among authors: lauro vd. Int J Mol Sci. 2020 Sep 4;21(18):6479. doi: 10.3390/ijms21186479. Int J Mol Sci. 2020. PMID: 32899866 Free PMC article. Review.
23 results